Primary and secondary prevention of ventricular arrhythmias in dilated cardiomyopathy: Nonsustained, sustained, and incessant

International Heart Journal

Volumn 50, Issue 6, 2009, Pages 741-751

  Meyer, Christian ^a   Schueller, Per ^a   Rodenbeck, Astrid ^b   Hennersdorf, Marcus ^c   Merx, Marc ^a   Winter, Joachim ^a   Rassaf, Tienush ^a   Kelm, Malte ^a   Schauerte, Patrick ^b  

^a HEINRICH HEINE UNIVERSITY   (Germany)

^b RWTH AACHEN UNIVERSITY   (Germany)

^c SLK Kliniken Heilbronn   (Germany)

Author keywords

Dilated cardiomyopathy; Implantable cardioverter defibrillator; Primary prevention; Ventricular tachyarrhythmia

Indexed keywords

AMIODARONE; ANGIOTENSIN II ANTAGONIST; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIGITALIS; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR;

ADULT; ARTICLE; CONGESTIVE CARDIOMYOPATHY; CONTROLLED STUDY; DEFIBRILLATOR; FEMALE; HEART VENTRICLE ARRHYTHMIA; HEART VENTRICLE FIBRILLATION; HEART VENTRICLE TACHYCARDIA; HUMAN; IMPLANTATION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SUDDEN DEATH;

ARRHYTHMIAS, CARDIAC; CARDIOMYOPATHY, DILATED; DEATH, SUDDEN, CARDIAC; DEFIBRILLATORS, IMPLANTABLE; HEART VENTRICLES; HUMANS; MIDDLE AGED; STROKE VOLUME;

EID: 74049140371     PISSN: 13492365     EISSN: 13493299     Source Type: Journal    
DOI: 10.1536/ihj.50.741     Document Type: Article

References (18)

1. Bardy GH, Lee KL, Mark DB, et al. Amiodarone or an implantable cardioverter-defibrillator for congestive heart failure. N Engl J Med 2005; 352: 225-37.
2. McClellan MB, Tunis SR. Medicare coverage of ICDs. N Engl J Med 2005; 352: 222-4.
3. Schoenfeld MH. Contemporary pacemaker and defibrillator device therapy: challenges confronting the general cardiologist. Circulation 2007; 115: 638-53. (Review)
4. Frankenstein L, Zugck C, Nelles M, Schellberg D, Remppis A, Katus H. Primary ICD-therapy in patients with advanced heart failure: selection strategies and future trials. Clin Res Cardiol 2008; 97: 594-600.
5. Cleland IG, Coletta AP, Clark AL. Clinical trials update from the American College of Cardiology 2007: ALPHA, EVEREST, FUSION II, VALIDD, PARR-2, REMODEL, SPICE, COURAGE, COACH, REMADHE, pro-BNP for the evaluation of dyspnoea and THIS-diet. Eur J Heart Fail 2007; 9: 740-5.
6. Kadish A, Dyer A, Daubert IP, et al. Prophylactic defibrillator implantation in patients with non-ischemic dilated cardiomyopathy. N Engl J Med 2004; 350: 2151-8.
7. Grimm W, Christ M, Bach J, Müller HH, Maisch B. Noninvasive arrhythmia risk stratification in idiopathic dilated cardiomyopathy: results of the Marburg Cardiomyopathy Study. Circulation 2003; 108: 2883-91.
8. Simon T, Becker R, Voss F, et al. Elevated B-type natriuretic peptide levels in patients with non-ischemic cardiomyopathy predict occurrence of arrhythmic events. Clin Res Cardiol 2008; 97: 306-9.
9. Schiller NB, Shah PM, Crawford M, et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 1989; 2: 358-67. (Review)
10. Sadoul N, Mletzko R, Anselme F, et al. Incidence and clinical relevance of slow ventricular tachycardia in implantable cardioverter- defibrillator recipients: an international multicenter prospective study. Circulation 2005; 112: 946-53.
11. Haverkamp W. Electrical storm: still a cryptogenic phenomenon? Eur Heart 12006; 27: 2921-2.
12. Böcker D, Block M, Isbruch F, et al. Comparison of frequency of aggravation of ventricular tachyarrhythmias after implantation of automatic defibrillators using epicardial versus nonthoracotomy lead systems. Am J Cardiol 1993; 71: 1064-8.
13. Karaoguz R, Maydanozcu S, Altun T, Güldal M, Akyürek O, Erol C. Appropriate ICD therapy in patients with idiopathic dilated cardiomyopathy: long term follow-up. Int Heart J 2006; 47: 763-73.
14. Schaer BA, Ammann P, Sticherling C, Zellweger MI, Cron TA, Osswald S. Prophylactic implantable cardioverter defibrillator therapy in dilated cardiomyopathy: impact of left ventricular function. Int J Cardiol 2006; 108: 26-30.
15. Grimm W, Hoffmann JJ, Müller HH, Maisch B. Implantable defibrillator event rates in patients with idiopathic dilated cardiomyopathy, nonsustained ventricular tachycardia on Holter and a left ventricular ejection fraction below 30%. J Am Coll Cardiol 2002; 39: 780-7.
16. Van der Velden LB, Huybrechts W, Adriaensens B, et al. Appropriate and inappropriate implantable cardioverter defibrillator interventions during secondary prevention. Acta Cardiol 2008; 63: 39-45.
17. Ellenbogen KA, Levine JH, Berger RD, et al. Are implantable cardioverter defibrillator shocks a surrogate for sudden cardiac death in patients with nonischemic cardiomyopathy? Circulation 2006; 113: 776-82.
18. Borggrefe M, Chen X, Martinez-Rubio A, et al. The role of implantable cardioverter defibrillators in dilated cardiomyopathy. Am Heart J 1994; 127: 1145-50. (Review)